Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial ...
Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results